These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review. Reginster JY Curr Pharm Des; 2005; 11(28):3711-28. PubMed ID: 16305506 [TBL] [Abstract][Full Text] [Related]
8. Ibandronate: the evolution of a once-a-month oral therapy for postmenopausal osteoporosis. Dempster DW; Bolognese MA J Clin Densitom; 2006; 9(1):58-65. PubMed ID: 16731432 [TBL] [Abstract][Full Text] [Related]
9. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. Miller PD; McClung MR; Macovei L; Stakkestad JA; Luckey M; Bonvoisin B; Reginster JY; Recker RR; Hughes C; Lewiecki EM; Felsenberg D; Delmas PD; Kendler DL; Bolognese MA; Mairon N; Cooper C J Bone Miner Res; 2005 Aug; 20(8):1315-22. PubMed ID: 16007327 [TBL] [Abstract][Full Text] [Related]
10. Ibandronate treatment for osteoporosis: rationale, preclinical, and clinical development of extended dosing regimens. Epstein S Curr Osteoporos Rep; 2006 Mar; 4(1):14-20. PubMed ID: 16527003 [TBL] [Abstract][Full Text] [Related]
11. A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. Reginster JY; Felsenberg D; Cooper C; Stakkestad JA; Miller PD; Kendler DL; Adami S; McClung MR; Bolognese MA; Civitelli R; Dumont E; Bonvoisin B; Recker RR; Delmas PD Osteoporos Int; 2006 Feb; 17(2):159-66. PubMed ID: 15959614 [TBL] [Abstract][Full Text] [Related]
12. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies. Schimmer RC; Bauss F Clin Ther; 2003 Jan; 25(1):19-34. PubMed ID: 12637110 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study. Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148 [TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age. Ettinger MP; Felsenberg D; Harris ST; Wasnich R; Skag A; Hiltbrunner V; Wilson K; Schimmer RC; Miller PD J Rheumatol; 2005 Oct; 32(10):1968-74. PubMed ID: 16206354 [TBL] [Abstract][Full Text] [Related]
15. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg. Epstein S; Jeglitsch M; McCloskey E Curr Med Res Opin; 2009 Dec; 25(12):2951-60. PubMed ID: 19835464 [TBL] [Abstract][Full Text] [Related]
16. Ibandronate: a review of its use in the management of postmenopausal osteoporosis. Frampton JE; Perry CM Drugs; 2008; 68(18):2683-707. PubMed ID: 19093707 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Reginster JY; Adami S; Lakatos P; Greenwald M; Stepan JJ; Silverman SL; Christiansen C; Rowell L; Mairon N; Bonvoisin B; Drezner MK; Emkey R; Felsenberg D; Cooper C; Delmas PD; Miller PD Ann Rheum Dis; 2006 May; 65(5):654-61. PubMed ID: 16339289 [TBL] [Abstract][Full Text] [Related]
19. [Ibandronate (Bonviva) in the treatment of postmenopausal osteoporosis]. Reginster JY Rev Med Liege; 2006 Nov; 61(11):783-6. PubMed ID: 17191748 [TBL] [Abstract][Full Text] [Related]
20. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy. Miller PD Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]